Trial Profile

A Phase 1b/2a Dose Escalation Study of BOLD-100 in Combination with FOLFOX Chemotherapy in Patients with Advanced Solid Tumours

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 29 May 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BOLD 100 (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Oxaliplatin (Primary)
Indications Adenocarcinoma; Biliary cancer; Cholangiocarcinoma; Colorectal cancer; Gallbladder cancer; Gastric cancer; Gastrointestinal cancer; Pancreatic cancer; Solid tumours
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Bold Therapeutics

Most Recent Events

16 Apr 2026 According to a Bold Therapeutics media release, the data from the trial will be presented at the American Association for Cancer Research (AACR) Annual meeting 2026.
16 Apr 2026 Results presented in a Bold Therapeutics media release.
30 Apr 2025 Results presented in a Bold Therapeutics Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com